Truist raised the firm’s price target on Beta Bionics (BBNX) to $32 from $28 and keeps a Buy rating on the shares. The company posted another solid beat and raise driven by new patient start upside and a $6M FY25 revenue guidance raise, the analyst tells investors in a research note. Truist adds that the accelerated pharmacy channel shift has even bigger positive out-year estimate implications.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics price target raised to $35 from $30 at Lake Street
- Beta Bionics price target raised to $31 from $26 at Stifel
- Beta Bionics price target raised to $33 from $26 at Goldman Sachs
- Beta Bionics price target raised to $23 from $17 at Baird
- Beta Bionics price target raised to $32 from $26 at Piper Sandler